about
Prognostication and response assessment in liver and pancreatic tumors: The new imagingPSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsPancreatic Neuroendocrine Neoplasms: Clinical Value of Diffusion-Weighted Imaging.Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways.True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugsFGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage.Profiling mTOR pathway in neuroendocrine tumors.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report.Pathological complete response in a patient affected by multiple synchronous, breast and lung primary malignancies: a case report and review of the literature.A prospective non-randomised single-center study comparing laparoscopic and robotic distal pancreatectomy.IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer.Digital Subtraction of Magnetic Resonance Images Improves Detection and Characterization of Pancreatic Neuroendocrine Neoplasms.Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase.A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes.Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.Correction: The Prostate Specific Membrane Antigen Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways1.Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study.Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment.Whole-genome landscape of pancreatic neuroendocrine tumours.Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.Mixed Adenoneuroendocrine Carcinomas of the Gastrointestinal Tract: Targeted Next-Generation Sequencing Suggests a Monoclonal Origin of the Two ComponentsPulmonary Adenocarcinoma With Enteric DifferentiationAnti-tumor effects of toxins targeted to the prostate specific membrane antigenErratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE
P50
Q27021568-159BD527-8701-4717-ABE0-F17BF78719C6Q27339832-63AF5B5D-5119-4507-9F0F-418FAD89E5D9Q31030832-6F561459-1B31-41B6-AABF-5B338DDDBF91Q33371769-6C9861D5-137D-4E9A-AB21-DDCABECE8C2DQ33412361-E2325E6B-2123-44C8-8720-2E1667163B96Q34510256-F6A22C0F-6E83-4C32-AB97-F4FF3E536495Q36524946-D8714B36-E9A4-4294-AF28-66A565489768Q36568998-C5E11677-ED03-4825-A82F-84B2256F2AA6Q37586258-FB29D312-F24B-48A9-A8B5-247B1F00D57DQ38034440-B62C7777-A937-4AC5-BAEC-8BBAE5C7FFAFQ38527936-F3F78B2A-5D5A-44BF-AA57-AFDDAAA7381CQ38776942-DA023F98-4EE3-4745-9788-ACC0DBCE8B9BQ39134761-787A3BDA-678D-4474-AA81-ECAC4E50D4DBQ39197444-CE449894-C983-4494-9131-511D0B8F9E6EQ39725373-5C2F8CAA-BA57-421A-874D-D5D65850B719Q40421673-2D1FAEAB-2350-49B5-80C3-A76352A9F894Q40609370-0A3AE7B7-7A5E-44FF-B874-E5500665A3BEQ44430715-FD4882C4-CDDE-4AF6-93CB-45E3EDBF55A5Q45134077-A5FFC273-E8CF-4946-B523-400BEC05DAA7Q45785941-E8080EC5-0057-43AB-A3FB-D3E685AF5B01Q46656356-A32D0206-A2F9-4B18-ACA2-1D8EE6D32B6FQ47864375-13F180A0-806D-49B8-AFBD-05615064F84DQ50792218-AC971B99-EBC2-4062-AAD2-DF9276AEAD72Q51137102-4FAEBC14-FFF3-456B-96D6-7AE83BE2E1A9Q52964782-A771C77F-E10D-4000-8502-7DFDCDDE91F7Q57425536-3C2D73FE-B5B2-48BC-AEA7-D69BDD8FE0E5Q60445852-661C0105-0541-4FAA-94D6-A351CA0D8FA4Q74719517-8935FBA7-84E9-46EA-83FF-4F3831616D51Q88676840-3AED9147-F4F2-4EE6-A679-ED20041334BF
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sara Cingarlini
@ast
Sara Cingarlini
@en
Sara Cingarlini
@es
Sara Cingarlini
@nl
type
label
Sara Cingarlini
@ast
Sara Cingarlini
@en
Sara Cingarlini
@es
Sara Cingarlini
@nl
prefLabel
Sara Cingarlini
@ast
Sara Cingarlini
@en
Sara Cingarlini
@es
Sara Cingarlini
@nl
P106
P21
P31
P496
0000-0003-4786-4781